Berthold A. Nock

3.6k total citations
110 papers, 2.8k citations indexed

About

Berthold A. Nock is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Berthold A. Nock has authored 110 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 74 papers in Radiology, Nuclear Medicine and Imaging and 61 papers in Epidemiology. Recurrent topics in Berthold A. Nock's work include Radiopharmaceutical Chemistry and Applications (73 papers), Neuroendocrine Tumor Research Advances (60 papers) and Peptidase Inhibition and Analysis (46 papers). Berthold A. Nock is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (73 papers), Neuroendocrine Tumor Research Advances (60 papers) and Peptidase Inhibition and Analysis (46 papers). Berthold A. Nock collaborates with scholars based in Greece, Netherlands and Switzerland. Berthold A. Nock's co-authors include Θεοδοσία Μάινα, Anastasia Nikolopoulou, Eric P. Krenning, Marion de Jong, Paul Cordopatis, Efstratios Chiotellis, Jean Claude Reubi, Aikaterini Kaloudi, Renzo Cescato and Beatrice Waser and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Medicinal Chemistry and Inorganic Chemistry.

In The Last Decade

Berthold A. Nock

107 papers receiving 2.8k citations

Peers

Berthold A. Nock
Θεοδοσία Μάινα Greece
Anastasia Nikolopoulou United States
Rosalba Mansi Switzerland
Erik de Blois Netherlands
Jack L. Erion United States
Carmen Wängler Germany
Wouter A.P. Breeman Netherlands
Gary L. Sieckman United States
A. Heppeler Switzerland
Jean‐Claude Schaer Switzerland
Θεοδοσία Μάινα Greece
Berthold A. Nock
Citations per year, relative to Berthold A. Nock Berthold A. Nock (= 1×) peers Θεοδοσία Μάινα

Countries citing papers authored by Berthold A. Nock

Since Specialization
Citations

This map shows the geographic impact of Berthold A. Nock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berthold A. Nock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berthold A. Nock more than expected).

Fields of papers citing papers by Berthold A. Nock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berthold A. Nock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berthold A. Nock. The network helps show where Berthold A. Nock may publish in the future.

Co-authorship network of co-authors of Berthold A. Nock

This figure shows the co-authorship network connecting the top 25 collaborators of Berthold A. Nock. A scholar is included among the top collaborators of Berthold A. Nock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berthold A. Nock. Berthold A. Nock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abouzayed, Ayman, A Mattsson, Vladimir Tolmachev, et al.. (2024). GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics. Pharmaceutics. 16(4). 513–513. 5 indexed citations
2.
Mattsson, A, Ayman Abouzayed, Berthold A. Nock, et al.. (2024). Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI Radiopharmacy and Chemistry. 9(1). 3 indexed citations
3.
Brandt, Marie, et al.. (2024). Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo Stability. Pharmaceutics. 16(3). 392–392. 2 indexed citations
4.
5.
Nock, Berthold A., et al.. (2023). Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists. Pharmaceuticals. 16(5). 674–674. 25 indexed citations
6.
Nock, Berthold A., Oleg G. Chepurny, George Loudos, et al.. (2022). Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study. Pharmaceutics. 14(3). 666–666. 6 indexed citations
7.
Nock, Berthold A., Aikaterini Kaloudi, Barbara Janota, et al.. (2021). [99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes. Cancers. 13(20). 5093–5093. 22 indexed citations
8.
Busstra, Martijn B., J. Fred Verzijlbergen, Mark Konijnenberg, et al.. (2021). GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients. Journal of Nuclear Medicine. 62(11). 1517–1523. 31 indexed citations
9.
Tiel, Sandra T. van, Joost Haeck, Gabriela N. Doeswijk, et al.. (2018). In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer. Molecular Imaging and Biology. 20(6). 973–983. 14 indexed citations
10.
Μάινα, Θεοδοσία, Aikaterini Kaloudi, Ibai E. Valverde, Thomas L. Mindt, & Berthold A. Nock. (2017). Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors. Nuclear Medicine and Biology. 52. 57–62. 14 indexed citations
11.
Kaloudi, Aikaterini, et al.. (2016). Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. Cancer Biotherapy and Radiopharmaceuticals. 31(1). 20–28. 23 indexed citations
12.
Dalm, Simone U., John W.M. Martens, Anieta M. Sieuwerts, et al.. (2015). In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. Journal of Nuclear Medicine. 56(5). 752–757. 56 indexed citations
13.
Chatalic, Kristell L.S., Mark Konijnenberg, Julie Nonnekens, et al.. (2015). In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies. Theranostics. 6(1). 104–117. 53 indexed citations
14.
Kaloudi, Aikaterini, et al.. (2015). In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands. Nuclear Medicine and Biology. 42(11). 824–832. 13 indexed citations
15.
Melis, Marleen, Erik de Blois, Wout A. P. Breeman, et al.. (2014). In Vivo Enzyme Inhibition Improves the Targeting of [ 177 Lu]DOTA-GRP(13–27) in GRPR-Positive Tumors in Mice. Cancer Biotherapy and Radiopharmaceuticals. 29(9). 359–367. 10 indexed citations
16.
Μάινα, Θεοδοσία, Renzo Cescato, Beatrice Waser, et al.. (2012). [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Research. 2(1). 25–25. 22 indexed citations
17.
Gabriel, Michael, Clemens Decristoforo, Ewald Wöll, et al.. (2011). [ 99m Tc]Demotensin VI: Biodistribution and Initial Clinical Results in Tumor Patients of a Pilot/Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 26(5). 557–563. 13 indexed citations
18.
Nikolopoulou, Anastasia, et al.. (2005). Tetraamine‐modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4‐2J cells and AR4‐2J tumor‐bearing mice. Journal of Peptide Science. 12(2). 124–131. 6 indexed citations
19.
Trejtnar, František, Milan Lázníček, Alice Lázníčková, et al.. (2005). 99mTc demotate 1: biodistribution and elimination characteristics in rats. Nuclear Medicine Communications. 26(6). 549–554. 3 indexed citations
20.
Gabriel, Michael, Clemens Decristoforo, Θεοδοσία Μάινα, et al.. (2004). 99m Tc-N 4 -[Tyr 3 ]Octreotate Versus 99m Tc-EDDA/HYNIC-[Tyr 3 ]Octreotide: An Intrapatient Comparison of Two Novel Technetium-99m Labeled Tracers for Somatostatin Receptor Scintigraphy. Cancer Biotherapy and Radiopharmaceuticals. 19(1). 73–79. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Θεοδοσία Μάινα Breakdown of academic impact, for papers by Anastasia Nikolopoulou Breakdown of academic impact, for papers by Rosalba Mansi Breakdown of academic impact, for papers by Erik de Blois Breakdown of academic impact, for papers by Jack L. Erion Breakdown of academic impact, for papers by Carmen Wängler Breakdown of academic impact, for papers by Wouter A.P. Breeman Breakdown of academic impact, for papers by Gary L. Sieckman Breakdown of academic impact, for papers by A. Heppeler Breakdown of academic impact, for papers by Jean‐Claude Schaer
Rankless by CCL
2026